A recent study has revealed that a treatment regimen combining daratumumab, lenalidomide, and limited dexamethasone significantly improves outcomes for older and frail patients with newly diagnosed multiple myeloma. This finding comes from the phase 3 IFM2017-03 trial, which compared this combination therapy against a standard treatment of lenalidomide with continuous dexamethasone.
According to research published in Lancet Oncology, at a median follow-up of 46.3 months, patients receiving the dexamethasone-sparing regimen experienced a median progression-free survival (PFS) of 53.4 months, significantly better than the 22.5 months observed in those treated with lenalidomide plus standard dexamethasone. This translates to a hazard ratio of 0.51, with a p-value of less than 0.0001, indicating a strong statistical significance in favor of the new regimen.
The study, led by Salomon Manier, MD PhD, an associate professor at the University Hospital of Lille in France, highlights the study’s relevance for frail patients who often face complex treatment decisions. The study included patients aged at least 65 years who were not candidates for high-dose chemotherapy or autologous stem cell transplant. Participants were required to have a frailty score of at least 2 to qualify for inclusion.
The dexamethasone-sparing treatment not only improved PFS but also demonstrated a high overall response rate (ORR) of 92%, compared to 85% in the control group. The proportion of patients achieving a very good partial response (VGPR) or better was 69% in the experimental arm, significantly surpassing the 51% in the control group, with a p-value of 0.0050.
Addressing Treatment Tolerance and Safety
The findings underscore the importance of managing treatment tolerance in older patients, who often experience higher rates of non-hematologic adverse effects and treatment discontinuation. The study authors emphasized that limiting exposure to dexamethasone, which is associated with adverse effects such as infections, hypertension, and hyperglycemia, can mitigate these risks.
The trial involved random assignments of patients into two groups: one receiving the experimental treatment with subcutaneous daratumumab, lenalidomide, and limited dexamethasone, while the control group received lenalidomide with continuous dexamethasone. In the experimental group, patients received daratumumab at 1800 mg weekly during the first two cycles, transitioning to bi-weekly and then monthly doses, alongside lenalidomide at 25 mg during the treatment cycles.
Safety data showed that the rates of any-grade adverse events were similar between the two groups, at 98% for both. However, the occurrence of serious adverse events was slightly lower in the dexamethasone-sparing group at 63% compared to 69% in the control group. The study noted that adverse events led to the discontinuation of at least one study drug in 30% of patients in the experimental group versus 34% in the control group.
Implications for Future Treatment Options
The results of the IFM2017-03 trial present a compelling case for the use of daratumumab in combination with lenalidomide as a standard of care for older patients with multiple myeloma. The research indicates that this approach can provide significant benefits without increasing toxicity, making it a valuable option in the treatment landscape.
Dr. Manier and his colleagues highlighted that while lenalidomide combined with dexamethasone has been the conventional treatment, the new findings suggest that introducing daratumumab could improve outcomes for frailer patients. As the medical community continues to explore innovative therapies for multiple myeloma, this trial’s outcomes may pave the way for more effective and safer treatment protocols.
In summary, the combination of daratumumab and lenalidomide with limited dexamethasone has shown significant promise in enhancing progression-free survival for older, frail patients newly diagnosed with multiple myeloma, potentially reshaping treatment strategies in this vulnerable population.
